Sen. John Ashcroft (R-MO) introduced new legislation that would make sure that cancer patients receive full access to drugs and cancer treatment services prescribed by physicians for the patients' recovery.
Sen. John Ashcroft (R-MO) introduced new legislation that would make sure that cancer patients receive full access to drugs and cancer treatment services prescribed by physicians for the patients' recovery.
"People who are fighting cancer are waging the toughest battle of their lives," said Ashcroft. "They should not be burdened further with the uncertainty of whether they will have access to life-saving medications. My new initiative will protect prescription drug benefits for cancer patients and will improve Medicare coverage of outpatient cancer treatment. This legislation will halt the administration's plan to cut Medicare services for cancer patients. We will not allow Washington bureaucrats to deny life-saving drugs and treatment to senior cancer patients and risk Americans' lives."
Ashcroft's Cancer Care Preservation Act will preserve funding for Medicare cancer treatment in physicians' offices and hospitals. The legislation prevents the administration from cutting Medicare reimbursements for outpatient cancer treatment. If the Health Care Financing Administration deems that changes in reimbursement rates are necessary, it must work with cancer patients, survivors, nurses and physicians to develop the changes; make certain that Medicare reimbursements for outpatient cancer care will cover all costs of providing services; and receive Congressional approval.
In August, Ashcroft sent a letter to senators urging them to support the Cancer Care Preservation Act. "Medicare beneficiaries with cancer must be confident that they will continue to receive the care they need, in the setting they choose, without risk of arbitrary and unexpected reductions in reimbursement that may force their doctors to cease offering treatment or refer them to a different facility for treatment," Ashcroft wrote. "I urge you to join with me in ensuring that our seniors receive full access to the life-saving therapies they need in the setting they choose." PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.